Retatrutide's mechanism of action centres on its simultaneous activation of GLP-1, GIP, and glucagon receptors
In those patients, addressing the underlying metabolic dysfunction first, through dietary intervention, GLP-1 therapy if indicated, or NAD+ support for cellular energy metabolism, is the clinical priority
Why did the AOD 9604 clinical trials fail
A mild stinging sensation is common with this compound because of its quinolinium chemistry
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice
Beyond simply breaking fat down, AOD9604 has been studied for its ability to limit new fat cell formation, making it useful for researchers investigating both sides of the fat accumulation equation in cell and animal models